Expression quantitative trait loci are genomic positions, typically single nucleotide variants, that correlate with differences in the activity of nearby genes. In classical eQTL studies, which aggregate gene expression measurements across whole tissues, these associations reveal only the average effect of a variant across a mixture of cell types. That averaging is a serious limitation for immunology, because peripheral blood contains dozens of specialized cell populations—T cells, natural killer cells, monocytes, B cells, and many rarer intermediates—each with its own regulatory grammar. A variant that strongly boosts a gene in natural killer cells may be invisible in a bulk measurement dominated by monocytes. By pairing each donor’s genome with single-cell transcriptomes, the researchers could test the association between genotype and expression separately within each cell population, resolving effects that bulk approaches blur away.

The technical pipeline behind the study was substantial. Whole-genome sequencing data were processed through established variant-calling workflows, with germline small variants identified using the Strelka2 caller, following best practices endorsed by the Global Alliance for Genomics and Health for benchmarking variant calls. Coverage calculations were performed with Mosdepth, and sequencing quality was assessed against community standards to ensure that the genetic data underpinning the eQTL analysis were reliable. On the transcriptomic side, single-cell RNA-seq data from the 230,000 PBMCs were integrated across donors using the Harmony method, a widely adopted algorithm that corrects for batch effects and donor-specific technical noise while preserving genuine biological differences between cell types. Cells were then classified into 18 populations spanning the major branches of the immune system, providing the cellular resolution required for cell-type-specific association testing.

With genotypes and cell-type-resolved expression in hand, the team carried out cis-eQTL mapping using Matrix eQTL, a computational framework designed to perform the enormous matrix operations required for fast association testing across millions of variants and thousands of genes. The result was a catalog of 1,233,644 cis-eQTLs distributed across the 18 cell types. Importantly, this was not simply a numbers exercise. The researchers subjected their findings to a series of validation and interpretive analyses designed to ask whether the variants they detected showed the hallmarks of genuine regulatory elements, and, more provocatively, what evolutionary forces have shaped them.

One of the most intriguing findings to emerge from these secondary analyses concerns evolutionary conservation. When the team examined the genomic regions harboring their strongest eQTLs, they found that the most statistically significant associations tended to sit in less conserved regions of the genome—stretches of DNA that have diverged relatively rapidly between species. These variants were also concentrated in the regulatory regions of more divergent genes. This pattern suggests that immune gene regulation is an evolutionary hotspot, consistent with the well-documented observation that genes involved in host defense are frequent targets of positive selection. Rapid turnover of regulatory elements may allow populations to adapt to changing pathogen landscapes, but it may also help explain why immune-related variants are a rich source of susceptibility to chronic inflammatory and autoimmune disease in modern humans. The finding carries a double edge: the same regulatory flexibility that enabled adaptation to ancient pathogens may predispose contemporary genomes to misfire.

To move from statistical association to mechanistic understanding, the researchers turned to deep learning models of cis-regulatory sequence. Neural networks trained on genomic data can learn the relationship between DNA sequence and regulatory function, predicting how transcription factors bind to specific sequence contexts and how single-base changes alter those interactions. Drawing on approaches pioneered by tools such as DeepSEA, Basset, and the Enformer-style sequence models developed in recent years, the team applied these computational models to their eQTL catalog to ask, for each variant, which transcription factor binding sites are disrupted and in which cellular context that disruption matters. This step transformed the analysis from a list of correlated positions into a functional hypothesis-generating resource: each eQTL could now be annotated with a predicted mechanism of action grounded in sequence-level regulatory biology.

The functional analysis focused on genes with well-established roles in immunity, including NKG7, members of the HLA family, MIF, and MS4A1. NKG7 encodes a protein essential for the cytotoxic function of natural killer cells and CD8 T cells, involved in the trafficking of lytic granules that deliver the killing blow to infected or malignant target cells; variants affecting its expression could plausibly modulate antiviral and antitumor immunity. HLA genes, which encode the human leukocyte antigen molecules that present viral peptides to T cells, are among the most polymorphic loci in the human genome and have been repeatedly implicated in COVID-19 susceptibility and severity. MIF, the macrophage migration inhibitory factor, is a potent inflammatory mediator whose circulating levels correlate with severe COVID-19 pneumonia. MS4A1, better known as CD20, defines B cells and is the target of widely used monoclonal antibody therapies. By tracing how variants influence the expression of these genes through disrupted transcription factor binding—including factors such as those involved in myeloid and lymphoid differentiation—the study connected genetic variation to plausible cellular mechanisms.

The disease context of the study is explicit in its framing. Prior work by overlapping teams had used single-cell transcriptomics to identify immune cell signatures associated with severe Delta-variant COVID-19, and large consortia had shown that severe disease is marked by a dysregulated myeloid cell compartment. The GWAS Catalog lists numerous loci associated with COVID-19 outcomes, but translating those associations into functional biology has remained a central challenge for the field. The new eQTL resource provides a bridge: because it assigns regulatory variants to specific immune cell types and annotates their predicted effects on gene expression, it can be used to prioritize candidate causal variants among the many statistical associations emerging from disease-genetic studies. The authors also point toward broader applications, noting parallels with single-cell eQTL studies in brain, autoimmune disease, and other contexts that have revealed how cell-type-specific regulation shapes genetic risk.

The scale of the cellular census deserves emphasis. Thirty donors may sound modest compared with the million-person cohorts of cardiovascular genetics, but single-cell eQTL studies trade sample size for resolution: every donor contributes tens of thousands of individual cells, each measured across the whole transcriptome. The 230,000-cell dataset allowed the researchers to detect eQTLs not only in abundant populations like CD4 T cells and monocytes but in rarer states such as intermediate monocytes and specific lymphocyte subsets, where regulatory effects would be hopelessly diluted in bulk analysis. The identification of 18 cell-type-resolved regulatory landscapes from this relatively small cohort illustrates the power of the approach, and the authors’ analytical strategy—conservation analysis, transcription factor modeling, and pathway interrogation—provides a template that larger consortia are likely to follow as single-cell eQTL mapping matures.

Methodologically, the study also underscores how much of modern genomics depends on careful assembly of open computational tools. Beyond the core machinery of variant calling and eQTL mapping, the researchers drew on annotation frameworks for regulatory elements derived from more than a thousand epigenomic datasets, packages for gene ontology and pathway enrichment, tools for predicting DNA shape features that influence transcription factor binding, and simulation frameworks for testing the significance of overlaps between genomic intervals. This layered infrastructure allowed a single research group to integrate population genetics, transcriptomics, chromatin biology, and machine learning into a coherent narrative about how sequence variation becomes functional variation in the immune system.

The limitations of the study are those inherent to its design. A cohort of 30 individuals restricts statistical power for detecting rarer variants and weaker regulatory effects, and the donor population limits generalizability across ancestries—an important consideration given that eQTL effects and linkage patterns differ among populations. The deep learning predictions, while mechanistically informative, remain computational hypotheses that would need experimental validation through reporter assays or CRISPR-based perturbation of individual variants. Nevertheless, the study’s value lies in the framework it establishes: a complete chain from genome sequence, through cell-type-resolved expression, to predicted transcription factor mechanism, anchored to a disease of global significance.

As single-cell sequencing costs continue to fall and paired genotyping-transcriptomics cohorts grow, resources of this kind are expected to expand rapidly in scale and diversity. What this study demonstrates is that the payoff of such investment is not merely a longer list of associations, but a progressively sharper picture of the regulatory code that governs human immunity—and with it, new opportunities to understand, predict, and ultimately intervene in diseases where the immune system holds the balance between recovery and catastrophe. For COVID-19, whose genetic architecture continues to be dissected years after the pandemic’s peak, that sharper picture may help explain at last why the same virus produces a mild illness in one person and a life-threatening one in another.

The review by Li, Zhu, Shen and colleagues examines two main routes for producing therapeutic immune cells. The first begins with peripheral blood mononuclear cells, a mixed population that includes lymphocytes and monocytes collected from a patient or donor. These cells can be isolated, activated and genetically modified before being returned to the recipient. The second route uses stem cells as a renewable starting material. Haematopoietic stem cells, which naturally generate blood and immune cells, can be expanded or redirected, while pluripotent stem cells can be differentiated into specialized immune populations under controlled laboratory conditions.

This distinction is important because conventional autologous cell therapies are laborious and variable. In an autologous process, a patient’s cells are collected, engineered and expanded before treatment. Disease, age, prior therapies and the condition of the patient’s immune system can all affect the quality and quantity of the starting material. Allogeneic manufacturing instead uses cells from a donor or a banked stem-cell line. A single engineered cell source may therefore be used to produce multiple treatment doses, allowing manufacturing to be performed in advance and under tightly controlled conditions.

Stem-cell engineering has expanded the range of immune cells that can be produced for therapy. T cells remain a central focus because they can identify abnormal cells through antigen-specific receptors and destroy them through cytotoxic mechanisms. Natural killer cells provide another route to immune-mediated killing and can recognize stressed or transformed cells without relying on the same antigen-recognition system as conventional T cells. Macrophages, which engulf material and influence inflammation, are also being developed as therapeutic agents. Each cell type offers distinct biological advantages, but each presents different challenges in generating a stable, potent and clinically useful product.

One of the most prominent technologies discussed in this field is the chimeric antigen receptor, or CAR. A CAR is a synthetic receptor introduced into an immune cell through genetic engineering. Its external binding region is designed to recognize a selected molecular marker, while internal signalling domains activate the cell after target engagement. CAR engineering has been particularly influential in T-cell therapy, but researchers are also adapting the technology for natural killer cells and macrophages. These CAR-equipped cells are intended to improve target recognition, strengthen activation and potentially overcome mechanisms that allow diseased cells to evade natural immunity.

Genetic modification can also be used to improve safety and immune compatibility. Researchers are investigating edits that reduce the ability of donor-derived cells to attack healthy recipient tissues, a complication associated with immune recognition across individuals. Other modifications may limit the capacity of therapeutic cells to trigger excessive inflammation, a process that can produce serious systemic effects. Gene engineering can additionally introduce “safety switches” or other control systems designed to eliminate or deactivate the cells if unwanted toxicity occurs. At the same time, reducing the expression of molecules recognized by the recipient’s immune system may help prolong the survival of transplanted cells.

The review also highlights the importance of differentiation platforms. Producing an immune cell from a stem cell is not simply a matter of adding one factor to a culture. Cells must receive carefully timed combinations of signalling molecules, growth factors and environmental cues that reproduce aspects of blood-cell development. Scientists are refining three-dimensional culture systems, feeder-free methods and scalable bioreactors to control this process. The objective is to generate large numbers of cells with a uniform identity, predictable function and minimal contamination by unwanted or incompletely differentiated cell types.

Manufacturing remains one of the field’s decisive tests. A clinically compatible process must preserve cell viability and activity while meeting strict standards for sterility, genetic stability and product consistency. Cells may need to be frozen, transported and stored without losing their therapeutic properties. Stem-cell-derived products also require extensive characterization to confirm that residual undifferentiated cells do not create safety risks. Advances in automation, closed-system processing and analytical technologies are helping researchers move from small laboratory batches toward reproducible production at a scale suitable for clinical use.

Early clinical evidence is beginning to shape expectations, but the review emphasizes that important questions remain. Researchers must determine how long engineered cells persist in the body, whether they continue functioning after repeated exposure to disease environments and how reliably they reach the tissues where they are needed. Tumours and chronic inflammatory conditions can suppress immune activity, while infectious diseases may impose rapidly changing biological pressures. Future studies will need to compare cell sources, genetic designs and manufacturing strategies directly, while also monitoring delayed toxicities and the long-term consequences of genome editing.

Together, these developments suggest that allogeneic immunotherapy could become a flexible platform rather than a single treatment type. Donor-derived and stem-cell-derived T cells, natural killer cells, macrophages and CAR-engineered variants may eventually be selected according to the disease, target and desired immune response. The review presents this convergence of gene engineering, stem-cell biology and bioprocessing as a foundation for more accessible cellular medicines. Its central message is that therapeutic success will depend not only on making immune cells powerful, but also on making them controllable, compatible, manufacturable and safe enough for broad clinical application.

Subject of Research: Allogeneic immunotherapy using genetically engineered and stem-cell-derived immune cells

Article Title: Allogeneic immunotherapy

Article References: Li, YR., Zhu, Y., Shen, X. et al. Allogeneic immunotherapy. Nat Rev Bioeng (2026). https://doi.org/10.1038/s44222-026-00468-w

Image Credits: AI Generated

DOI: 10.1038/s44222-026-00468-w

Keywords: Allogeneic immunotherapy, cell-based immunotherapy, stem cell engineering, T cells, natural killer cells, macrophages, CAR-engineered cells, gene editing, pluripotent stem cells, therapeutic cell manufacturing

The study employed a one-color microarray platform, utilizing SurePrint G3 Human Unrestricted 8×60K arrays paired with Agilent’s SureScan Microarray Scanner, facilitating extensive transcriptome-wide profiling of PBMCs. The selection of PBMCs as a source of genetic material was strategic, capitalizing on their accessibility through peripheral blood draws and their reflective capacity of systemic pathological states. The cohort consisted of sixteen subjects, evenly divided between patients with luminal A breast cancer and matched healthy controls, ensuring a controlled comparative framework. Subsequently, the team applied the robust “limma” package alongside the versatile “tidyverse” suite in the R environment to identify differentially expressed lncRNAs with statistical stringency, controlling for false discovery rates to mitigate type I errors.

Results highlighted significant dysregulation of several lncRNA classes, notably long intergenic non-coding RNAs (LINC), LOC genes, and antisense transcripts. Of particular interest was LINC00974, which exhibited a marked increase in expression in cancer patients compared to controls, with a log fold change exceeding 1.5 and an FDR-adjusted p-value of 0.03. This rigorously validated differential expression underscores LINC00974’s potential as a sensitive and specific biomarker for early-stage breast cancer detection. The biological significance of LINC00974 is supported by previous literature elucidating its role in oncogenic pathways, primarily through mechanisms involving microRNA sponging—a process that modulates availability of miRNAs, consequently regulating downstream gene expression patterns pivotal in cell proliferation, migration, and tumor metastasis.

Fascinatingly, the functional enrichment analysis revealed that differentially expressed lncRNAs cluster into gene networks linked to oncogenesis and tumor progression. The integration of findings from the LncRNADisease 2.0 database further confirmed associations between these lncRNAs and diverse oncological disorders, suggesting a shared molecular regulatory framework underpinning multiple cancer types. This cross-cancer relevance amplifies the translational potential of targeting such lncRNAs, not only as diagnostic markers but also as therapeutic candidates, offering a novel axis for precision medicine approaches.

The discovery that lncRNA alterations are detectable in PBMCs, peripheral blood cells, is particularly noteworthy. This finding supports the concept that systemic blood components mirror tumor-derived molecular signatures, circumventing the need for invasive tissue biopsies. It opens avenues for blood-based liquid biopsy tests, which could revolutionize breast cancer screening by providing a simple, non-invasive, and repeatable method for early diagnosis and monitoring. Considering the aggressive nature of breast cancer metastasis and the importance of early intervention for favorable outcomes, such biomarker development is urgently needed.

Importantly, LINC00974’s involvement in chromatin remodeling and RNA stabilization provides mechanistic insights into how non-coding RNAs orchestrate complex regulatory networks within the tumor microenvironment and circulating immune cells alike. These processes influence the epigenetic landscape and post-transcriptional control of gene expression, directly impacting tumor cell behavior and immune responses. Understanding these pathways could unravel new targets for pharmaceutical modulation and shed light on resistance mechanisms to conventional therapies.

The study’s limitations, acknowledged by the authors, include the relatively small sample size, which, while sufficient for exploratory analysis, necessitates validation in larger cohorts to corroborate these findings and establish clinical utility. Future work will focus on functional assays to confirm the biological roles of these candidate lncRNAs and refine their specificity and sensitivity profiles. Techniques such as quantitative PCR will be employed to validate expression levels independently, ensuring robustness of the biomarker candidates.

A compelling direction for upcoming research is the longitudinal monitoring of lncRNA expression changes through treatment and disease progression. Such dynamic profiling could enable personalized therapeutic adjustments and provide prognostic information, potentially identifying patients at higher risk of relapse or metastasis. It also aligns with emerging trends in oncology toward integrating molecular diagnostics with patient management, fostering a move toward precision health.

The implications of this research extend beyond breast cancer, as the molecular principles governing lncRNA function appear conserved across multiple cancer types. This lends weight to the hypothesis that lncRNAs contribute to the hallmarks of cancer and represent a largely untapped reservoir of molecular targets. The intersection of non-coding RNA biology with immunology, as illustrated by PBMC analyses, may uncover novel avenues to modulate immune surveillance and tumor-immune interactions.

Moreover, the methodology showcased in this study exemplifies the power of combining high-throughput technologies with sophisticated computational tools to unveil subtle yet clinically meaningful molecular alterations. The study integrates bioinformatics pipelines adept at multiple testing correction and functional enrichment, highlighting best practices in omics research for reliable biomarker discovery.

In summary, this pioneering investigation elucidates the altered landscape of long non-coding RNAs in peripheral blood mononuclear cells of luminal A breast cancer patients, underscoring LINC00974 as a frontrunner biomarker candidate. Its detectability in blood and involvement in oncogenic pathways position it as a potential game-changer in early cancer detection and targeted therapy development. As subsequent studies expand upon these findings, the vision of minimally invasive, lncRNA-based diagnostic assays for breast cancer edges closer to reality, promising to enhance patient outcomes through timely intervention and personalized care.

Subject of Research: Long non-coding RNAs in peripheral blood mononuclear cells associated with luminal A breast cancer

Article Title: Non-coding RNAs in Peripheral Blood Mononuclear Cells in Luminal A Breast Cancer

News Publication Date: 13-Aug-2025

Web References:

• Journal: Gene Expression
• DOI: 10.14218/GE.2025.00021

Keywords: Long noncoding RNA, Breast cancer, Luminal A, Peripheral blood mononuclear cells, LINC00974, Biomarkers, Microarray analysis, Oncogenic pathways, miRNA sponging, Gene expression regulation

VEXAS syndrome, an acronym for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome, arises from somatic mutations in the UBA1 gene that encodes the ubiquitin-activating enzyme E1. These mutations disrupt the ubiquitination pathway, a critical cellular process that tags proteins for degradation, thereby maintaining proteostasis and immune regulation. Understanding the downstream immune perturbations has remained challenging due to the rarity and complexity of the disease. The recent transcriptome analysis fundamentally advances this understanding by mapping gene expression alterations at a cellular level, providing rich mechanistic insight.

The study utilized high-throughput RNA sequencing of peripheral blood mononuclear cells (PBMCs) isolated from patients diagnosed with VEXAS syndrome and compared them to matched healthy controls. This unbiased, wide-spectrum approach enabled the identification of distinct transcriptional signatures and cell population dynamics that define the immunological dysfunction in VEXAS. The rigorous statistical models and bioinformatic pipelines implemented ensured the robustness of the findings, correlating clinical features with molecular profiles.

One pivotal revelation from the transcriptomic profiling was the profound dysregulation of myeloid lineage cells in VEXAS patients. Particularly, monocytes exhibited an aberrant activation state characterized by upregulated expression of pro-inflammatory cytokines and genes responsible for antigen presentation pathways. This hyperactivation likely contributes to the intense systemic inflammation observed clinically, manifesting with fevers, cytopenias, and bone marrow dysplasia. Additionally, neutrophilic granulocytes showed altered gene expression patterns associated with enhanced degranulation and reactive oxygen species production, further perpetuating tissue damage.

Concurrently, the study unveiled perturbations in lymphoid populations, specifically within subsets of T cells. There was evidence of exhaustion markers upregulation and skewing toward phenotypes indicative of chronic antigen exposure. These observations suggest that persistent inflammation drives T-cell dysfunction, potentially impairing adaptive immunity and predisposing patients to opportunistic infections. This lymphoid compartment dysfunction highlights the broader immune dysregulation beyond innate immunity components.

Notably, Mizumaki and colleagues uncovered transcriptional signatures implicating disrupted interferon signaling pathways, which are critical for antiviral responses and immunomodulation. The precise nature of interferon dysregulation varied among individual patients, suggesting heterogeneity in immune impairment. However, consistent attenuation or hyperactivation elements were observed across the cohort, underlining a pivotal role for interferon cascades in disease pathophysiology. These insights open potential avenues for targeted therapeutic interventions aimed at restoring immune balance.

The transcriptomic landscape also revealed aberrations in cellular metabolic pathways, particularly those governing mitochondrial function and oxidative phosphorylation. Specifically, immune cells exhibited signatures compatible with metabolic reprogramming, a feature increasingly recognized as integral in chronic inflammation and immune cell differentiation. This metabolic shift possibly sustains the hyperinflammatory milieu, supporting pathogenic immune cell persistence and activity.

An intriguing aspect of the study was the integration of transcriptomic data with clinical phenotyping and disease severity metrics. Machine learning algorithms allowed for stratification of patients based on molecular profiles, which corresponded with differences in organ involvement and treatment responses. This stratification suggests that transcriptomic profiling may serve as a prognostic tool, enabling personalized medicine approaches tailored to individual immune dysfunction patterns.

The authors meticulously detail the potential implications for novel therapeutic targets emerging from their findings. Inhibition of specific cytokine pathways, restoration of ubiquitin-proteasome system function, and modulation of metabolic circuits present viable strategies. Furthermore, the paper discusses how current therapeutics, such as corticosteroids and immunosuppressants, often inadequately address the transcriptomic anomalies, rationalizing the need for more precise interventions.

Future research directions, as highlighted by the investigators, will likely revolve around longitudinal monitoring of transcriptomic changes pre- and post-treatment to capture dynamic immune changes. Such studies could elucidate mechanisms of therapeutic resistance and relapse. Moreover, extending studies to larger multiethnic cohorts stands to clarify the role of genetic and environmental modifiers in disease expression.

Importantly, this research underscores the utility of advanced omics technologies in rare disease research, exemplifying how transcriptomics can unravel complex immune dysfunctions that elude traditional diagnostic tools. The comprehensive dataset presented by Mizumaki et al. lays the groundwork for integrated systems immunology approaches that will revolutionize understanding of VEXAS and related autoinflammatory syndromes.

The study’s collaborative efforts across multi-institutional teams reflect the growing imperative for interdisciplinary work in tackling enigmatic diseases. By marrying clinical expertise with computational biology, the authors provide a blueprint for how modern science can confront challenges that arise at the intersection of genetics, immunology, and molecular pathology.

At a broader level, these findings resonate with ongoing efforts to decipher the landscape of somatic mutations contributing to adult-onset inflammatory diseases. The revelation that somatic UBA1 mutations can reshape immune transcriptomes with such profound clinical consequences prompts reconsideration of pathogenic mechanisms behind other poorly understood autoinflammatory disorders.

In conclusion, the in-depth transcriptomic profiling presented in this landmark study profoundly enriches the scientific community’s grasp of immune dysfunction in VEXAS syndrome. It not only delineates key pathological pathways but also heralds opportunities for biomarker discovery and targeted therapeutics. As research continues, the hope is that patients suffering from this debilitating disease will benefit from more precise, effective treatment strategies born from molecular insights.

Subject of Research: Transcriptomic profiling of immune dysregulation in patients with VEXAS syndrome

Article Title: In depth transcriptomic profiling defines a landscape of dysfunctional immune responses in patients with VEXAS syndrome

Article References:
Mizumaki, H., Gao, S., Wu, Z. et al. In depth transcriptomic profiling defines a landscape of dysfunctional immune responses in patients with VEXAS syndrome. Nat Commun 16, 4690 (2025). https://doi.org/10.1038/s41467-025-59890-0

Image Credits: AI Generated